Hebei Senlang Biotechnology Co.
Latest round
- Series B
Last raised
- Dec 2018
Total raised
- Undisclosed
Investors
- 1
About Hebei Senlang Biotechnology Co.
,Ltd operates as a developer of tumor cell immunotherapy. The company's Founder and CSO, Jianqiang Li has over 20 years of experience in immunology and cell therapy, published 13 papers in Nature Medicine, Blood, and Journal of Immunology. As of 2022, the company has 160 employees. Its cell therapy technology platforms include chimeric antigen receptor (CAR) T-cells (CAR-T), allogeneic CAR Gamma Delta T-cells (CAR-GDT), and armored tumor-infiltrating lymphocytes (armTILs). Its CAR-T cell therapy portfolio consists of multiple autologous and allogeneic candidates. Its CAR-T candidates can against relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), T-cell ALL (T-ALL), non-Hodgkin's lymphoma(NHL), and T-cell lymphoblastic lymphoma.
Who invested in Hebei Senlang Biotechnology Co.
1 investor across 1 round
See all investors in Hebei Senlang Biotechnology Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Dec 7, 2018
Amount
Undisclosed
Investors
Questions about Hebei Senlang Biotechnology Co.
Who invested in Hebei Senlang Biotechnology Co.?
Hebei Senlang Biotechnology Co. has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Hebei Senlang Biotechnology Co. raised?
Hebei Senlang Biotechnology Co. has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Hebei Senlang Biotechnology Co. last raise money?
Hebei Senlang Biotechnology Co.'s most recent round on record is a Series B, in Dec 2018.
What does Hebei Senlang Biotechnology Co. do?
,Ltd operates as a developer of tumor cell immunotherapy.
Where is Hebei Senlang Biotechnology Co. headquartered?
Hebei Senlang Biotechnology Co. is headquartered in Shijiazhuang, China.
Which VCs invest in companies like Hebei Senlang Biotechnology Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Hebei Senlang Biotechnology Co.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Hebei Senlang Biotechnology Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.